




RealRate

# PHARMACEUTICAL 2020

Entasis Therapeutics Holdings Inc.  
Rank 279 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2020

## Entasis Therapeutics Holdings Inc. Rank 279 of 362



The relative strengths and weaknesses of Entasis Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entasis Therapeutics Holdings Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Entasis Therapeutics Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 276% points.

The company's Economic Capital Ratio, given in the ranking table, is -439%, being 137% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	49,006
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,556
Liabilities, Non-Current	1,321
Other Assets	1,683
Other Compr. Net Income	9.0
Other Expenses	677
Other Liabilities	0
Other Net Income	0
Property and Equipment	345
Research and Development	40,166
Revenues	10,763
Selling, General and Administrative Expense	13,770

Output Variable	Value in 1000 USD
Assets	51,034
Liabilities	8,877
Expenses	54,613
Stockholders Equity	42,157
Net Income	-43,850
Comprehensive Net Income	-43,846
Economic Capital Ratio	-439%

